Sino Biological, Inc., founded in 2007, is recognized as a global leader in recombinant technology for the life sciences. The company specializes in the production of recombinant proteins and antibodies, gene synthesis, and offers CRO services crucial for both life sciences research and drug development.
Its notable facilities include the Center for Bioprocessing (C4B) based in Houston, Texas, which is adept in mammalian cell-based protein and antibody production. Meanwhile, SignalChem Biotech (SCB) located in Vancouver, Canada, focuses on kinase-related reagents, stable cell line development, and therapeutic discovery initiatives.
The latest financial milestone for Sino Biological, Inc. saw a significant investment of CNY4.98B through an IPO on 01 August 2021. The company strategically positions itself to provide innovative, high-quality solutions to a wide range of global academic and industrial clients. The company's strong presence across North America underscores its robust capabilities in supporting biotechnology advancements worldwide.